Affimed is a biotechnology business based in the US. Affimed shares (AFMD) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.18 – the same closing value as a week prior. Affimed employs 76 staff and has a trailing 12-month revenue of around $5.6 million.
Terms and conditions apply*. For 401k rollovers, existing SoFi IRA members must complete 401k rollovers via this link For SoFi members without a SoFi IRA, a SoFi IRA must first be opened, and 401k rollover must be completed utilizing Capitalize via this link. SoFi and Capitalize will charge no additional fees to process a 401(k) rollover to a SoFi IRA. SoFi is not liable for any costs incurred from the existing 401k provider for rollover. Please check with your 401k provider for any fees or costs associated with the rollover. For IRA contributions, only deposits made via ACH and cash transfer from SoFi Bank accounts are eligible for the match. Click here for the 1% Match terms and conditions.
Must be a SoFi Plus member at the time a recurring deposit is received into your SoFi Active or Automated investing account to qualify. Bonus calculated on net monthly recurring deposits made via ACH and paid out as Rewards Points. See Rewards Terms of Service. SoFi reserves the right to change or terminate this promotion at any time without notice. See terms and limitations. https://www.sofi.com/sofiplus/invest/#disclaimers
Open an account.Provide your personal information and sign up.
Fund your account.Deposit funds into your account by linking your banking information or transfer funds from another trading account.
Search for the stock name – AFMD.Search for the stock by name or ticker symbol.
Buy the stock. Place your order. It's that simple.
Buy Affimed stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.
7 of 7
What is the Finder Score?
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Affimed stock price (NASDAQ: AFMD)
Use our graph to track the performance of AFMD stocks over time.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Affimed price performance over time
Historical closes compared with the close of $0.1815 from 2025-05-19
1 week (2025-07-07)
N/A
1 month (2025-06-14)
N/A
3 months (2025-04-17)
-75.26%
6 months (2025-01-17)
-84.22%
1 year (2024-07-18)
-96.66%
2 years (2023-07-18)
-97.04%
3 years (2022-07-18)
28.6
5 years (2020-07-17)
44.15
Affimed financials
Revenue TTM
$5.6 million
Gross profit TTM
$5.6 million
Return on assets TTM
-49.42%
Return on equity TTM
-149.49%
Profit margin
0%
Book value
$1.05
Market Capitalization
$3 million
TTM: trailing 12 months
Affimed share dividends
We're not expecting Affimed to pay a dividend over the next 12 months.
Have Affimed's shares ever split?
Affimed's shares were
split on a 1:10 basis on 10 March 2024
. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Affimed shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Affimed shares which in turn could have impacted Affimed's share price.
Affimed share price volatility
Over the last 12 months, Affimed's shares have ranged in value from as little as $0.0701 up to $5.84. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Affimed's is 2.072. This would suggest that Affimed's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Affimed overview
Affimed N. V. , a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. It has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and strategic collaboration agreement with Genentech for the development of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers.
Frequently asked questions
null What percentage of Affimed is owned by insiders or institutions? Currently 6.007% of Affimed shares are held by insiders and 19.886% by institutions.How many people work for Affimed? Latest data suggests 76 work at Affimed.When does the fiscal year end for Affimed? Affimed's fiscal year ends in December.Where is Affimed based? Affimed's address is: Gottlieb-Daimler-Straße 2, Mannheim, Germany, 68165What is Affimed's ISIN number? Affimed's international securities identification number is: NL0010872420What is Affimed's CUSIP number? Affimed's Committee on Uniform Securities Identification Procedures number is: N01045108
Looking to invest in AI stocks? Here are some of the best artificial intelligence stocks available, along with tips to better understand AI investments.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
Advertiser disclosure
Finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which Finder receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. Finder compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
How likely would you be to recommend Finder to a friend or colleague?
0
1
2
3
4
5
6
7
8
9
10
Very UnlikelyExtremely Likely
Required
Thank you for your feedback.
Our goal is to create the best possible product, and your thoughts, ideas and suggestions play a major role in helping us identify opportunities to improve.
